Project Grant F32DK145142
- Project Grant Award Summary Massachusetts General Hospital's Research Management Division received a $842,732 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded July 8, 2026, with completion targeted for April 30, 2031. The project delivers research services focused on developing and validating pathway-specific polygenic scores (PPGSs) to predict...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Monell Chemical Senses Center a $2.24 million Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 5, 2025, with completion targeted for May 31, 2030. This award funds comprehensive research to unravel the neural mechanisms underlying satiety and weight loss induced by glucagon-like peptide-1 (GLP1)-based obesity drugs...
- Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Massachusetts General Hospital a $156,510 Project Grant (CFDA 93.847: Diabetes, Digestive, and Kidney Diseases Extramural Research) effective July 1, 2026, through March 31, 2030. Under the direction of Dr. Lee, the award funds development of a precision metabolic risk stratification framework for Type 2 Diabetes (T2D) prevention in patients with Major Depressive Disorder (MDD). The research...
- Grant Award Summary The National Institutes of Health (NIH) Office of the Director awarded a $1.61 million Project Grant (CFDA 93.310: Trans-NIH Research Support) to The Regents of the University of Colorado, doing business as University of Colorado-Denver, with an award date of June 15, 2026, and ultimate completion date of April 30, 2031. The project, titled "Investigating Brain Plasticity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial," delivers...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases awarded a $203,244 Project Grant to The Regents of the University of California, San Francisco (UCSF) on May 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports the "Assessment of Body Composition in Adolescents with Type 2 Diabetes on Glucagon-Like-Peptide Receptor Agonists" (ABC Study), a clinical research...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), a Harvard Medical School-affiliated academic medical center, received a $201,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective August 1, 2025, through July 31, 2027. This R03 award supports a discrete, well-defined research project that expands upon a parent...
- Federal Project Grant Award Summary Duke University's Office of Research Administration was awarded $417,354 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on December 11, 2025, with a completion date of June 30, 2026. The research project, titled "A Substrate for Durable Gut-Brain Signaling," investigates the biological mechanisms underlying long-term food...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Boston Children's Hospital a $3.1 million Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 3, 2025, with a completion date of September 2, 2029. This award supports basic biomedical research investigating the role of lipogenic (fat-producing) pathways in intestinal remodeling following Roux-en-Y gastric bypass...
- Federal Grant Award Summary Boston University Medical Campus received a $168,252 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, through July 31, 2030. The award supports a five-year research and career development initiative conducted by an Assistant Professor of Medicine in the Section of Endocrinology, Diabetes,...
- Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1.58 million Project Grant to the University of California, Los Angeles (UCLA) on July 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds the NIDDK HERITAGE study, a research initiative designed to develop comprehensive tandem repeat (TR) resources and advance understanding of the genetic architecture underlying...
GENETIC INSIGHTS INTO TASTE PREFERENCES AND THEIR IMPACT ON METABOLIC DISEASE AND GLP-1 RECEPTOR AGONIST RESPONSE - PROJECT SUMMARY/ABSTRACT THE TYPE 2 DIABETES (T2D) AND OBESITY EPIDEMIC POSE SIGNIFICANT PUBLIC HEALTH AND ECONOMIC BURDEN. WHILE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP1-RA) SPARKED MUCH OPTIMISM, THEIR EFFECTIVENESS FOR TREATING METABOLIC DISEASE IS HIGHLY HETEROGENEOUS. IDENTIFYING NOVEL GENETIC FACTORS THAT PREDICT METABOLIC DISEASE RISK AND MODULATE GLP1-RA RESPONSES IS CRITICAL TO ATTENUATE THE PUBLIC HEALTH BURDEN OF THESE DISEASES. PARTICULARLY IN HYPERPALATABLE FOOD ENVIRONMENTS, TASTE PREFERENCES ARE POTENTIAL TARGETS. THEY VARY SUBSTANTIALLY, ARE HIGHLY HERITABLE, AND INFORM DIET QUALITY WHICH DRIVES METABOLIC DISEASE. AS GENES INFLUENCING TASTE PREFERENCE ARE IMPLICATED IN EATING BEHAVIOR AND METABOLISM, VARIATIONS IN THESE GENES MAY HELP PREDICT INDIVIDUALS MORE SUSCEPTIBLE TO UNHEALTHY FOOD CHOICES AND METABOLIC DISEASE. MANY PATIENTS ALSO REPORT THAT GLP1-RAS CHANGE TASTE PREFERENCES, PROMOTING HEALTHIER FOOD CHOICES AND TREATMENT SUCCESS FOR SOME, AND TASTE AVERSIONS THAT LEAD TO TREATMENT DISCONTINUATION FOR OTHERS. TASTE PREFERENCES MAY THEREFORE HELP PREDICT WHICH INDIVIDUALS ARE MORE SUSCEPTIBLE TO EACH TYPE OF TASTE CHANGE, PROVIDING TARGETS TO PREDICT GLP1-RA EFFECTIVENESS. GENETICS APPROACHES--SUCH AS GENOME-WIDE ASSOCIATION STUDIES (GWAS), MENDELIAN RANDOMIZATION (MR) AND POLYGENIC SCORES (PGS)--CAN BE USEFUL TOOLS TO CHARACTERIZE THE BIOLOGICAL BASIS OF TASTE PREFERENCES, DEFINE THEIR IMPACT ON METABOLIC DISEASE RISK, AND DETERMINE WHETHER TASTE-RELATED GENETIC FACTORS CAN PREDICT GLP1- RA RESPONSE, PROVIDING FACTORS TO LEVERAGE IN PRECISION MEDICINE AND PHARMACOGENETICS OF METABOLIC DISEASE. THE PROPOSED RESEARCH AIMS TO UNDERSTAND THE IMPACT OF GENETIC DETERMINANTS OF TASTE PREFERENCE ON METABOLIC DISEASE RISK AND GLP1-RA RESPONSE. IN AIM 1 I WILL PERFORM THE LARGEST GWAS OF 5 TASTE PREFERENCES, TO-DATE; THEN I WILL ELUCIDATE THE CAUSAL MECHANISMS THROUGH WHICH GENETIC DETERMINANTS OF TASTE PREFERENCE IMPACT METABOLIC DISEASE. IN AIM 2 I WILL BUILD PGS FOR 5 TASTE PREFERENCES IN TWO CLINICAL STUDIES ON GLP1-RA TO DETERMINE WHETHER GENETIC DETERMINANTS OF TASTE PREFERENCE CAN PREDICT CHANGES IN DIETARY HABITS AND METABOLIC BENEFITS ON A GLP1-RA, THEREBY PROVIDING NOVEL GENETIC PREDICTORS OF GLP1-RA RESPONSE. COMPLETING THIS WORK WILL REVEAL FUNDAMENTAL INSIGHT INTO THE BIOLOGICAL BASIS OF TASTE PREFERENCES AND THEIR IMPACT ON METABOLIC DISEASE RISK AND GLP1-RA RESPONSE, PROVIDING NOVEL GENETIC TARGETS TO IMPROVE THE EFFECTIVENESS OF PRECISION MEDICINE AND PHARMACOGENETIC APPROACHES FOR METABOLIC DISEASE PREVENTION AND TREATMENT. THE NSRA FELLOWSHIP WILL PROVIDE ME WITH COMPREHENSIVE TRAINING IN LARGE-SCALE GENOMICS AND GENETIC CAUSAL INFERENCE. THE CENTER FOR GENOMIC MEDICINE IN MASSACHUSETTS GENERAL HOSPITAL AND THE BROAD INSTITUTE PROVIDE UNPARALLELED ENVIRONMENTS FOR TRAINEES. THE PROPOSED PROJECT, WITH MENTORSHIP SUPPORT, WILL PROVIDE FOUNDATIONAL SKILLS TRAINING, SCIENTIFIC AND CAREER MENTORSHIP, AND PROFESSIONAL DEVELOPMENT TO PREPARE THE CANDIDATE TO APPLY FOR A CAREER DEVELOPMENT AWARD WITH THE LONG-TERM GOAL OF BECOMING AN INDEPENDENT INVESTIGATOR INTEGRATING SENSORY NUTRITION AND GENOMICS TO ADVANCE PRECISION MEDICINE FOR METABOLIC HEALTH. 1
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $79.5k | 4/21/26 |